{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:28:17Z","timestamp":1792099697978,"version":"4.4.0"},"reference-count":22,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:00:00Z","timestamp":1757462400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["TropicalMed"],"abstract":"<jats:p>Background and Aims: Hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV) remain significant global public health issues despite advances in their diagnosis and treatment. Our country is in a medium endemic region for HBV. Reactivation can occur during or after immunosuppressive therapy. Therefore, screening patients before treatment is crucial to prevent reactivation. However, pretreatment screening is often insufficiently emphasized in studies. This study aimed to assess the incidence of HBV and pretreatment screening rates in patients with solid organ tumors at our center. Methods: We included patients aged over 18 years who were treated for solid organ tumors at our center between January 2016 and January 2022. Data on age, sex, histopathological diagnosis, and serological parameters were retrospectively collected. Appropriate HBV screening was defined as the assessment of HBsAg, anti-HBs, and anti-HBc IgG levels prior to the initiation of immunosuppressive therapy. Results: In our study, HBsAg testing was requested for 13.3% of the patients, and anti-HCV testing was requested for 13.3%. Among the patients screened for HBV and HCV, the prevalence rates of HBV and HCV infection were 3.3% and 1%, respectively. Conclusions: Our findings reveal inadequate screening rates for HBV and HCV among patients receiving immunosuppressive therapy. Increasing awareness about screening and implementing regular educational programs are crucial to protect patients from reactivation.<\/jats:p>","DOI":"10.3390\/tropicalmed10090258","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T14:14:55Z","timestamp":1757513695000},"page":"258","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prevalence and Screening Rates of Hepatitis B and Hepatitis C Infections in Adult Patients with Solitary Organ Tumors"],"prefix":"10.3390","volume":"10","author":[{"given":"Seyhmus","family":"Abakay","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Dokuz Eylul University Hospital, Izmir 35000, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4032-9209","authenticated-orcid":false,"given":"H\u00fcseyin","family":"D\u00f6ngelli","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Dokuz Eylul University Hospital, Izmir 35000, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3939-3089","authenticated-orcid":false,"given":"Nilay","family":"Dan\u0131\u015f","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Dokuz Eylul University Hospital, Izmir 35000, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9593-0942","authenticated-orcid":false,"given":"Halil \u0130brahim","family":"Ellez","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dokuz Eylul University Hospital, Izmir 35000, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00f6ksel","family":"Bengi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Dokuz Eylul University Hospital, Izmir 35000, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tu\u011fba","family":"Yavuz\u015fen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dokuz Eylul University Hospital, Izmir 35000, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7083-8517","authenticated-orcid":false,"given":"H\u00fcseyin Salih","family":"Semiz","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dokuz Eylul University Hospital, Izmir 35000, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","article-title":"Estimations of worldwide prevalence of chronic hepatitis B virus infection: A systematic review of data published between 1965 and 2013","volume":"386","author":"Schweitzer","year":"2015","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.cmi.2015.06.028","article-title":"Seroprevalence of hepatitis B and C virus infections and risk factors in Turkey: A fieldwork TURHEP study","volume":"21","author":"Tozun","year":"2015","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_3","first-page":"426","article-title":"Hepatitis B Reactivation in HBsAg-negative Anti-HBc-positive patients receiving cytotoxic chemotherapy for solid tumors","volume":"83","author":"Fidan","year":"2020","journal-title":"Acta Gastro-Enterol. Belg."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/S2468-1253(22)00050-4","article-title":"Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: A systematic review","volume":"7","author":"Alberts","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/path.4449","article-title":"HIV and the spectrum of human disease","volume":"235","author":"Lucas","year":"2015","journal-title":"J. Pathol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.pop.2020.02.011","article-title":"Human Immunodeficiency Virus in Adolescents: Risk, Prevention, Screening, and Treatment","volume":"47","author":"Chang","year":"2020","journal-title":"Prim. Care"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Brasseur, M., Heurgu\u00e9-Berlot, A., Barbe, C., Brami, C., Rey, J.B., Vella-Boucaud, J., Dabouz, F., Desl\u00e9e, G., Grange, F., and Volet, J. (2015). Prevalence of hepatitis B and C and sensibility of a selective screening questionnaire in patients receiving chemotherapy for solid tumors. BMC Cancer, 15.","DOI":"10.1186\/s12885-015-2033-z"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1055\/s-0033-1345722","article-title":"Immunosuppression and HBV reactivation","volume":"33","author":"Shouval","year":"2013","journal-title":"Semin. Liver Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/j.gastro.2014.10.039","article-title":"American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy","volume":"148","author":"Reddy","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2017). EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J. Hepatol., 67, 370\u2013398.","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1200\/JCO.20.01757","article-title":"Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update","volume":"38","author":"Hwang","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s12072-021-10239-x","article-title":"APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy","volume":"15","author":"Lau","year":"2021","journal-title":"Hepatol. Int."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"30","DOI":"10.7326\/M15-1121","article-title":"Hepatitis B Virus Reactivation and Prophylaxis During Solid Tumor Chemotherapy: A Systematic Review and Meta-analysis","volume":"164","author":"Paul","year":"2016","journal-title":"Ann. Intern. Med."},{"key":"ref_15","unstructured":"(2012). Medical Laboratories\u2014Requirements for Quality and Competence (Standard No. ISO 15189:2012)."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"S774","DOI":"10.4103\/0973-1482.174544","article-title":"Hepatitis B and C rates are significantly increased in certain solid tumors: A large retrospective study","volume":"14","author":"Kocoglu","year":"2018","journal-title":"J. Cancer Res. Ther."},{"key":"ref_17","first-page":"1","article-title":"Recommendations for identification and public health management of persons with chronic hepatitis B virus infection","volume":"57","author":"Weinbaum","year":"2008","journal-title":"MMWR Recomm. Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/cld.883","article-title":"Reactivation of Hepatitis B Virus: A Review of Clinical Guidelines","volume":"15","author":"Myint","year":"2020","journal-title":"Clin. Liver Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1365-2036.2009.04158.x","article-title":"Screening for hepatitis B in chemotherapy patients: Survey of current oncology practices","volume":"31","author":"Tran","year":"2010","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Hwang, J.P., Fisch, M.J., Lok, A.S., Zhang, H., Vierling, J.M., and Suarez-Almazor, M.E. (2013). Trends in hepatitis B virus screening at the onset of chemotherapy in a large US cancer center. BMC Cancer, 13.","DOI":"10.1186\/1471-2407-13-534"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S2468-1253(22)00386-7","article-title":"Global reporting of progress towards elimination of hepatitis B and hepatitis C","volume":"8","author":"Cui","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1053\/j.gastro.2024.11.008","article-title":"AGA Clinical Practice Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation in At-Risk Individuals","volume":"168","author":"Ali","year":"2025","journal-title":"Gastroenterology"}],"container-title":["Tropical Medicine and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2414-6366\/10\/9\/258\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:43:21Z","timestamp":1760035401000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2414-6366\/10\/9\/258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,10]]},"references-count":22,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["tropicalmed10090258"],"URL":"https:\/\/doi.org\/10.3390\/tropicalmed10090258","relation":{},"ISSN":["2414-6366"],"issn-type":[{"value":"2414-6366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,10]]}}}